Want to see ABVC full AI Analyst Report?
ABVC BioPharma (ABVC) AI Stock Analysis
ABVC BioPharma
(NASDAQ:ABVC)
ABVC's very low score is primarily driven by acute fundamental weaknesses, including negative revenue, high cash burn, and a complete lack of profitability. While technical indicators show a mild short-term price recovery, the company's deeply negative valuation metrics and sustained long-term downtrend highlight substantial risk and a continued reliance on external financing.
ABVC BioPharma (ABVC) vs. SPDR S&P 500 ETF (SPY)
- Market Cap
- $26.69M
- Dividend Yield
- ―
- Average Volume (3M)
- 100.33K
- Price to Earnings (P/E)
- -3.4
- Beta (1Y)
- 1.84
- Revenue Growth
- -100.00%
- EPS Growth
- -55.90%
- Country
- US
- Employees
- 18
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Biotechnology
ABVC BioPharma Business Overview & Revenue Model
Company Description
ABVC BioPharma, Inc. is a clinical-stage biopharmaceutical company focused on creating novel drugs and medical devices to address critical, underserved healthcare requirements across the United States. The company's pipeline includes several key cand...
How the Company Makes Money
ABVC’s revenue model is primarily based on monetizing its drug-development pipeline rather than selling established commercial products. The company seeks to generate income through (1) out-licensing and collaboration agreements, where third parties...
ABVC BioPharma Financial Statement Overview
Summary
Financial performance is severely pressured, scoring the minimum due to negative revenue, heavy net losses, and continuous cash burn, despite some recent debt reduction on the balance sheet.
Income Statement
12Very NegativeBalance Sheet
58NeutralCash Flow
18Very Negative| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | -795.95K | 0 | 509.59K | 152.43K | 969.78K | 355.80K |
| Gross Profit | -795.95K | 0 | 508.83K | -149.61K | 683.37K | 350.71K |
| EBITDA | -7.75M | -7.43M | -4.34M | -6.33M | -15.20M | -10.97M |
| Net Income | -7.90M | -7.91M | -4.90M | -7.79M | -16.42M | -12.84M |
Balance Sheet | ||||||
| Total Assets | 19.40M | 21.06M | 7.54M | 7.78M | 10.93M | 13.70M |
| Cash, Cash Equivalents and Short-Term Investments | 94.36K | 745.83K | 928.55K | 796.09K | 1.47M | 5.94M |
| Total Debt | 1.76M | 3.47M | 3.20M | 2.77M | 3.41M | 3.34M |
| Total Liabilities | 7.13M | 7.76M | 6.82M | 6.53M | 6.34M | 4.83M |
| Stockholders Equity | 10.29M | 11.11M | 1.23M | 1.55M | 4.45M | 8.84M |
Cash Flow | ||||||
| Free Cash Flow | -2.45M | -2.99M | -1.81M | -4.21M | -7.52M | -7.62M |
| Operating Cash Flow | -2.69M | -2.99M | -1.81M | -4.19M | -7.40M | -7.60M |
| Investing Cash Flow | -597.42K | -1.21M | 0 | -360.19K | -1.72M | -805.97K |
| Financing Cash Flow | 2.17M | 4.64M | 1.98M | 3.87M | 4.01M | 10.00M |
ABVC BioPharma Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For ABVC, the sentiment is Negative. The current price of 1.01 is above the 20-day moving average (MA) of 1.00, above the 50-day MA of 0.99, and below the 200-day MA of 1.26, indicating a neutral trend. The MACD of 0.01 indicates Negative momentum. The RSI at 48.26 is Neutral, neither overbought nor oversold. The STOCH value of 68.45 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for ABVC.
ABVC BioPharma Risk Analysis
ABVC BioPharma disclosed 48 risk factors in its most recent earnings report. ABVC BioPharma reported the most risks in the "Finance & Corporate" category.
Latest Risks Added
1 New RiskABVC BioPharma Peers Comparison
Overall Rating
INKT55Neutral
CAMP50Neutral
JSPR48Neutral
CRVO42Neutral
HYFT41Neutral- ABVC39Underperform
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| INKT | 55Neutral | $53.73M | -4.41 | 83.45% | ― | ― | 15.65% |
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
| CAMP | 50Neutral | $248.50M | -1.77 | -314.08% | ― | 40.21% | 13.40% |
| JSPR | 48Neutral | $17.31M | -0.33 | -618.87% | ― | ― | 73.74% |
| CRVO | 42Neutral | $24.19M | -0.50 | -156.02% | ― | -95.74% | -23.18% |
| HYFT | 41Neutral | $53.24M | -4.31 | -144.31% | ― | -26.89% | 56.50% |
| ABVC | 39Underperform | $26.69M | -3.39 | -71.47% | ― | -100.00% | -55.90% |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| ABVC | ABVC BioPharma, Inc. | 1.00 | -1.82 | -64.54% | |
| CRVO | Cervomed Inc. | 1.60 | -5.42 | -77.21% | |
| HYFT | Mindwalk Holdings Corp. | 1.13 | -0.63 | -35.80% | |
| JSPR | Jasper Therapeutics, Inc. | 0.52 | -1.29 | -71.27% | |
| INKT | Mink Therapeutics, Inc. | 10.53 | -2.28 | -17.80% | |
| CAMP | CAMP4 Therapeutics Corporation | 3.96 | 0.19 | 5.04% |
ABVC BioPharma Corporate Events
ABVC BioPharma Completes BioKey Cayman Spin-Off Transaction
NeutralOn August 21, 2026, ABVC BioPharma completed the legal and structural separation of its subsidiary, BioKey (Cayman), Inc., distributing roughly 15% of BioKey Cayman’s ordinary shares to ABVC common stockholders as a pro rata dividend. Sharehold...
ABVC BioPharma Delays Planned BioKey Share Distribution
NeutralOn August 3, 2026, ABVC BioPharma postponed the planned distribution of ordinary shares of its subsidiary BioKey (Cayman), Inc., which had been scheduled for that same date. The move is intended to give the company more time to complete administrativ...
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Sep 16, 2026